Filing Details

Accession Number:
0001209191-23-000204
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-03 16:24:38
Reporting Period:
2022-12-29
Accepted Time:
2023-01-03 16:24:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1745020 Theseus Pharmaceuticals Inc. THRX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1581754 B. James Tananbaum 900 Larkspur Landing Circle
Suite 150
Larkspur CA 94939
No No Yes No
1792204 Foresite Capital Fund V, L.p. 900 Larkspur Landing Circle
Suite 150
Larkspur CA 94939
No No Yes No
1792205 Foresite Capital Opportunity Fund V, L.p. 900 Larkspur Landing Circle
Suite 150
Larkspur CA 94939
No No Yes No
1792206 Foresite Capital Management V, Llc 900 Larkspur Landing Circle
Suite 150
Larkspur CA 94939
No No Yes No
1792207 Foresite Capital Opportunity Management V, Llc 900 Larkspur Landing Circle
Suite 150
Larkspur CA 94939
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-29 250,000 $5.00 3,585,346 No 4 P Indirect See Footnote
Common Stock Acquisiton 2022-12-29 250,000 $5.00 1,209,275 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
  2. The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.